Trial: 201907092

A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

Phase

I

Principal Investigator

Van Tine, Brian

Disease Site

Anus; Breast; Colon; Esophagus; Liver; Lung; Other Digestive Organ; Ovary; Pancreas; Rectum; Small Intestine; Soft Tissue; Stomach; Urinary Bladder

Learn more about this study at: clinicaltrials.gov